Woof. See what happened for April 6th's session?

StockWireNews

Time's Up: Past Champ (ALBT) Has Multiple Must-See Oversold Technicals (5 Overall Potential Breakout Catalysts)

April 11th

Greetings Readers,

Woof. See what happened for April 6th's session?

I alerted a new Nasdaq breakout idea at the opening bell.

All it did from there was catch fire to surge to a new 1.5 month high from an open of $.5702 to a high of $.847.

When the dust settled, that Nasdaq profile had rocketed approximately 48% intraday.

It gets even better when you consider that wasn't my first big runner over the past month.

Take a look at the results of these previous alerts (approx. runs):

  • 4/4 - 40%
  • 3/24 - 23%
  • 3/16 - 61%

That's 4 total champs over the past 4 weeks totaling a combined 172% (approx.) in short term/intraday runs.

Like I said, woof.

Listen. If you've been following this newsletter for a while, you know we're not ones to live in the past. We move forward.

But to move forward this time, we're going to take a look back at a past Nasdaq champ.

On multiple occasions over the past year, we've alerted this profile only to see it go on major double-digit moves in the short term.

Now, pair that knowledge with this profile's low float of fewer than 4Mn shares, multiple oversold leaning technicals signaling strong bounce potential, and several big press releases in the first 3rd of 2023.

Ready to get a jump on it? Pull up this Nasdaq breakout idea now:

*Avalon GloboCare Corp. (ALBT)*

Avalon GloboCare Corp. (Former ticker "AVCO") is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome-based ACTEX technology, as well as cell therapy related companion diagnostics.

And right now, ALBT has several potential breakout catalysts that are must-know material. Check them out:

No. 1 - A Low Float Could Allow For Explosive Volatility (Daily)

No. 2 - Multiple Oversold Technicals May Be Signaling HUGE Bounce/Reversal Potential

No. 3 - Company Acquires 40% Interest In Premier Laboratory (Portfolio Continues To Grow)

No. 4 - Game-Changing Patent News (Company Expands Robust IP Portfolio)

No. 5 - Company's Fusion Gene Map Technology Seen As Major Breakthrough

But more on those in a second...

Avalon GloboCare’s Revolutionary Research

Avalon is a clinical-stage, vertically integrated, leading “CellTech” bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well related diagnostics and therapeutics.

image

The Company also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets.

Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, the Company is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and other related vaccine and therapeutics.

Their core focus, at the moment, is their 3rd Generation CAR-T therapy that can potentially be useful in the treatment of cancer and other life-threatening diseases along with their FLASH-CAR technology and stem cell derived Exosome technology called ACTEX. ACTEX can be used to treat a wide variety of conditions, from neurodegenerative disorders to immune health, orthopedic applications, wound management, and even weight management.

The “QTY Code” Breakthrough Technology

Avalon recently announced a new research study applying artificial intelligence (AI) enhanced protein design “QTY Code” technology. The method is expected to accelerate the development of therapeutic monoclonal antibodies to treat cancer.

The research demonstrates a novel method for quickly predicting the design of so-called “water-loving” or hydrophilic variant structures of the 14 glucose transport membrane proteins in cells, which allows researchers to study the proteins more easily in water. Glucose transport membrane proteins are deregulated in many tumor types and are a potentially important target for cancer therapy.

The “QTY Code” breakthrough technology, developed by Avalon and the laboratory of Dr. Shuguang Zhang, Ph.D. MIT’s Media Lab in Boston, MA, is a protein-design platform that can turn water-insoluble transmembrane receptor proteins into water-soluble proteins, enabling their use in many clinical applications, including drug development.

A team of scientists led by Dr. Zhang applied the QTY code to the 14 glucose transport membrane proteins that transport sugar to cells. They used Google’s AlphaFold2, a DeepMind AI program, which can accurately and quickly predict how proteins fold. Dr. Zhang and his team used the QTY code with the open-source AlphaFold2 to predict the structures of these proteins in both their natural hydrophobic shapes and their QTY-code altered water-soluble shapes.

Click here for more QTY code info.

Avalon Files To Protect “IP”

Recently, Avalon jointly filed 16 patent applications, and co-invented with key strategic partners, including a top-5 U.S. university, a leading education and research center in Europe, as well as a premier multi-national developer of cellular therapies in the field of oncology. Patents were filed with the U.S. Patent and Trademark Office (USPTO), the China National Intellectual Property Administration (CNIPA), and under the Patent Cooperation Treaty (PCT) covering 36 countries.

The new intellectual property covers three core patent families:

Engineering and bio-manufacturing of novel CAR T-cells related to the mRNA-based Flash-CARTM cellular therapy platform. This technology has been applied to Avalon’s AVA-011 CAR-T cell therapy candidate, which is currently at the process development stage to generate cGMP-grade CAR-T cells for upcoming first-in-human clinical trials.

Soluble, antibody-like cytokine/chemokine decoy receptors derived from the QTY protein design, with potential applications including mitigation of the “cytokine storm” associated with CV-19 and cellular immunotherapy delivery, as well as broadening the range of therapeutic targets addressable by CAR T-cell therapies.

Novel S-layer coated emulsome technology (SLET)-derived fusion proteins intended for mucosal vaccine development, which are designed to trigger robust protective immune responses at the predominant sites of pathogen infection. The SLET platform provides a “molecular GPS system” to guide the trafficking and delivery of a payload to a targeted destination in the body.

Find more patent info here.

-----

And right now, multiple potential catalysts could once again fuel a vertical chart move in the near term for ALBT. They are:

No. 1 ALBT Potential Catalyst - A Low Float Could Allow For Explosive Volatility (Daily)

According to the Yahoo Finance website, ALBT has a low float.

The website reports this profile to have approximately 3.23Mn shares in its float.

Why is that important? It's important on one crucial level. Volatility.

Could more positive company news early this year help provide a near term spark?

-----

No. 2 ALBT Potential Catalyst - Multiple Oversold Technicals May Be Signaling HUGE Bounce/Reversal Potential

As of 12:00PM EST Monday, Barchart was reporting this profile to have several oversold leaning technicals.

These technicals could be signaling a healthy reversal could be approaching in the near term.

Here's the definition of a "reversal" from Investopedia:

"A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart."

Now, here are some key technicals (as of 12:00PM EST Monday) that could signal ALBT to be leaning oversold and on the verge of a potential reversal.

  • 9-Day Relative Strength Index: 30.97%
  • 14-Day Relative Strength Index: 34.82%

When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued.

  • 14-Day Raw Stochastic: 8.56%
  • 14-Day Williams %R: 91.44%

As the Raw Stochastic nears the 10% range and lower and the Williams %R nears the 90% range or higher, these technical indicators may also be viewed as oversold and undervalued.

Keep an eye on these technicals closely.

-----

No. 3 ALBT Potential Catalyst - Company Acquires 40% Interest In Premier Laboratory (Portfolio Continues To Grow)

Avalon GloboCare Announces Closing of Strategic In-vest-ment in Laboratory Services MSO, a Leading Clinical Diagnostics and Reference Laboratory Company

Transaction Expected to Be Accretive to Earnings Through Pro-fit Sharing Agreement

Adds Strong Clinical Synergies to Existing Avalon Portfolio

Marks Launch of New Roll-Up Strategy Targeting Toxicology and Pharmacogenetic Laboratories

FREEHOLD, N.J., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that it has acquired a 40% interest in Laboratory Services MSO, LLC (“LSM”), a premier clinical diagnostics and reference laboratory. Headquartered in Costa Mesa, California, LSM provides a broad portfolio of diagnostic tests including drug testing, toxicology, pharmacogenetics, and a broad array of test services, from general bloodwork to anatomic pathology. Specific capabilities include STAT blood testing, qualitative drug screening, genetic testing, urinary testing, sexually transmitted disease testing and more. LSM has a sophisticated and state-of-the-art facility for clinical diagnostics and reference laboratory. It has also developed a premier reputation for customer service satisfaction and fast turnaround time in the industry. LSM has completed over 600,000 tests since inception and currently has two operational locations in California.

...

David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon, commented, “We are excited to close this initial in-vest-ment as a first step, and anticipate acquiring a controlling interest within the next nine months. Not only is this transaction expected to be accretive to our earnings, we believe it also adds strong clinical and roll-up synergies to the existing Avalon portfolio and future growth plan. By combining LSM’s established infrastructure with Avalon’s cutting-edge diagnostic and cellular immunotherapy platforms, it provides us with an established roadmap and framework in the context of integrating our CellTech/therapeutic programs with precision medicine.

Our goal is to take advantage of a unique roll-up opportunity within the highly fragmented market for laboratory testing and services. By targeting laboratories with exceptional performance, positive revenue track record and niche-market advantage, we believe we can effectively leverage LSM’s experience and infrastructure to achieve significant synergies with respect to revenue growth and market shares, concluded Dr. Jin.

...

Read the full article here.

-----

No. 4 ALBT Potential Catalyst - Game-Changing Patent News (Company Expands Robust IP Portfolio)

Avalon GloboCare Announces Issuance of Key U.S. Patent for Multiple Novel QTY-Code Modified Cytokine and Chemokine Protein Receptor Molecules

Patent Jointly Filed with the Massachusetts Institute of Technology (MIT)

FREEHOLD, N.J., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technologies and therapeutics and laboratory testing provider, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,555,060, titled “QTY Fc Fusion Water Soluble Receptor Proteins.” The issued claims cover the composition of matter and methodology for multiple novel QTY-code modified cytokine and chemokine protein receptor molecules. The patent was jointly filed with Dr. Shuguang Zhang of the Massachusetts Institute of Technology (MIT).

...

We are pleased to be granted this key patent by the USPTO which expands our intellectual property portfolio,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. “We have jointly filed 16 patent applications, co-invented with key strategic partners, including a top-5 U.S. university, a leading education and research center in Europe, as well as a premier multi-national developer of cellular therapies in the field of oncology, and this issuance further enhances our position as a leader in immuno-oncology and cellular medicines.

The QTY code protein design platform, which was developed together with Professor Shuguang Zhang’s laboratory at MIT, can turn water-insoluble proteins that normally reside within cellular membranes—and that can be difficult to work within the laboratory—into water-soluble proteins that can be potentially used in many clinical applications. The resulting soluble, antibody-like cytokine/chemokine decoy receptors derived using the QTY protein design, have many potential applications including mitigation of the 'cytokine storm' associated with CV-19 and cellular immunotherapy delivery, as well as broadening the range of therapeutic targets addressable by CAR T-cell therapies,” concluded Dr. Jin.

Read the full article here.

-----

No. 5 ALBT Potential Catalyst - Company's Fusion Gene Map Technology Seen As Major Breakthrough

Avalon GloboCare Announces the Deployment of Breakthrough Fusion Gene Map Technology

Enabling the Development and Commercialization of Companion Diagnostics and Novel Therapeutic Targets for Leukemia Patients

FREEHOLD, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technologies and therapeutics and laboratory testing provider, today announced that it has deployed a breakthrough fusion gene map technology to be used for the goal of developing companion diagnostic kits and devices to enhance personalized clinical management of leukemia patients.

In collaboration with the Lu Daopei Institute of Hematology, a fusion gene map database from over 1,000 patients with leukemia was established and the results were previously published in the Blood Cancer Journal. Fusion genes are important genetic abnormalities in leukemia. Using advanced gene sequencing technology, called “Whole Transcriptome Sequencing” (WTS), multiple previously unknown fusion genes were identified which may potentially establish novel diagnostic and therapeutic targets.

Fusion genes are crucial in the diagnosis and treatment of leukemia. All well-known fusion genes are founder variations and constitute critical causative factors and can serve as important indicators of disease diagnosis,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. “Avalon is applying the bioinformatics from the fusion gene map with the goal of accelerating the development and commercialization of companion diagnostic kits and devices to enhance personalized clinical management of leukemia patients. The first diagnostic prototype is expected to enter clinical study and regulatory filing stage during Q3 of 2023. The fusion gene map technology also provides an unprecedented opp. to identify and validate fusion gene products as potential novel therapeutic targets. Additionally, this gives us an opp. to expand Avalon’s R&D pipeline and intellectual property portfolio.

Read the full article here.

-----

ALBT Recap: These Potential Catalysts Could Fuel A Vertical Move For This Past Champ

No. 1 - A Low Float Could Allow For Explosive Volatility (Daily)

No. 2 - Multiple Oversold Technicals May Be Signaling HUGE Bounce/Reversal Potential

No. 3 - Company Acquires 40% Interest In Premier Laboratory (Portfolio Continues To Grow)

No. 4 - Game-Changing Patent News (Company Expands Robust IP Portfolio)

No. 5 - Company's Fusion Gene Map Technology Seen As Major Breakthrough

-----

Coverage is officially reinitiated on ALBT. When time permits, do this:

image

Get ALBT on your radar now.

Sincerely,

Kai Parker

StockWireNews


(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)

StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company. Disclosure: I am not a lice.nsed finan.cial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. StockWireNews full disclosure is to be read and fully understood before using StockWireNews website, or joining StockWireNews' email or text list. By viewing StockWireNews website and/or reading StockWireNews email or text newsletter you are agreeing to StockWireNews full disclosure which can be read at www.stockwirenews.net/disclosure An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates fierceinvestor . com (“FI”), and owns and operates stockstreetwire . com ("SSW"). From time to time, StockWireNews, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Ownership of "FI" and "SSW" has now moved to a single individual. Avalon GlobalCare Corp. previously changed its ticker symbol from (AVCO) to (ALBT). Pursuant to an agreement between SWN Media LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 1/31/22 and ending on 2/1/22 to publicly disseminate information about (AVCO) via Website, Email and SMS. SWN Media LLC was paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (AVCO). Pursuant to an agreement between SWN Media LLC and TD Media LLC, StockWireNews has been hired for a period beginning on 8/3/22 and ending on 8/4/22 to publicly disseminate information about (AVCO) via Website, Email and SMS. SWN Media LLC was paid seven thousand five hundred USD via bank wire transfer. We own zero shares of (AVCO). Pursuant to an agreement between SWN Media LLC and TD Media LLC, StockWireNews has been hired for a period beginning on 10/9/22 and ending on 10/11/22 to publicly disseminate information about (AVCO) via Website, Email and SMS. SWN Media LLC was paid two thousand five hundred USD via bank wire transfer. We own zero shares of (AVCO). Pursuant to an agreement between SWN Media LLC and TD Media LLC, StockWireNews has been hired for a period beginning on 11/8/22 and ending on 11/9/22 to publicly disseminate information about (AVCO) via Website, Email and SMS. SWN Media LLC was paid ten thousand USD via bank wire transfer. We own zero shares of (AVCO). Pursuant to an agreement between SWN Media LLC and TD Media LLC, StockWireNews has been hired for a period beginning on 12/18/22 and ending on 12/20/22 to publicly disseminate information about (ALBT) via Website, Email and SMS. SWN Media LLC was paid five thousand USD via bank wire transfer. We own zero shares of (ALBT). Pursuant to an agreement between SWN Media LLC and TD Media LLC, StockWireNews has been hired for a period beginning on 1/17/23 and ending on 1/18/23 to publicly disseminate information about (ALBT) via Website, Email and SMS. SWN Media LLC was paid five thousand USD via bank wire transfer. We own zero shares of (ALBT). Pursuant to an agreement between SWN Media LLC and TD Media LLC, StockWireNews has been hired for a period beginning on 2/13/23 and ending on 2/13/23 to publicly disseminate information about (ALBT) via Website, Email and SMS. SWN Media LLC was paid five thousand USD via bank wire transfer. We own zero shares of (ALBT). Pursuant to an agreement between SWN Media LLC and TD Media LLC, StockWireNews has been hired for a period beginning on 4/10/23 and ending on 4/12/23 to publicly disseminate information about (ALBT) via Website, Email and SMS. SWN Media LLC was paid seventeen thousand five hundred USD via bank wire transfer. We own zero shares of (ALBT). To date we have been compensated a total of eighty thousand USD via bank wire transfer to disseminate information about (ALBT). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 04/10/2023 and ending on 04/14/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional twenty five thousand dollars USD. To date we have been paid one million sixty two thousand five hundred dollars USD to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US) lifewatermedia.com/albt-disclosure-31/